Medtronic (MDT) Highlights New Data from CRYO4PERSISTENT AF Clinical Trial Evaluating Patients with Symptomatic Persistent AF Treated with Cryoballoon at 2018 ESC Congress
Tweet Send to a Friend
Medtronic plc (NYSE: MDT) today announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life, reduced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
